Acrongenomics will use the net proceeds for the ongoing development of the Nano-Jeta platform as well as general corporate purposes
Acrongenomics, a publicly traded research and development nanobiotechnology company pioneering the development of uniquely advanced nano-molecular diagnostics, has announced the closing of the 1,000,000 share private placement financing at $4.00 per share as of Friday 16 December 2005.
"The success of this financing illustrates a strong confirmation of our approach, giving us the opportunity to focus on delivering advanced nanotechnology research to the life sciences industry.
"By putting together our scientific excellence and strong financial base, we have managed to complete this private placement financing earlier than expected," said Constantine Poulios, Acrongenomics's vice president.
Acrongenomics also announces that it is proceeding to obtain an independent evaluation of its technology from a certified reference laboratory.
